Information Provided By: 
Fly News Breaks for March 13, 2019
AMRN
Mar 13, 2019 | 07:35 EDT
Citi analyst Joel Beatty conducted a survey of 325 U.S. physicians to assess views related to Amarin's Vascepa. Of the doctors that were "very familiar" with the Reduce-It results, 84% provided positive comments regarding the study, Beatty tells investors in a research note. Further, prior authorization requirements are seen as a "major barrier" to Vascepa use, the analyst adds. He keeps a Buy rating on Amarin.
News For AMRN From the Last 2 Days
There are no results for your query AMRN
